4 results
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
We need objective and validated tests for the assessment of the severity of impairment in CFS/ME patients. In 2 areas these tests will be essential: for studies of the effect of interventions and for the assessment of disability.Hardly any research…
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
To investigate the effect of low-dose rhythmic transdermal 17-β-estradiol on serum P1NP (marker of bone formation) and CTX (marker for bone resorption), versus continuous low-dose and standard-dose continuous transdermal 17-β-estradiol…